Rotating Nursing Beds in Australia – TGA Registration, the Sponsor Role and Support at Home Funding

Most export markets ask two questions about a care bed. Can we sell it here, and will anyone pay for it. Australia answers the first in a way most suppliers recognise, and the second in a way they usually don't.

Since 1 November 2025, funding for an older person living at home has run through Support at Home, which replaced the Home Care Package programme. Assistive technology is not bought from the participant's quarterly budget. It comes through a separate scheme, assessed in tiers, and most of what sits on that scheme's list costs far less than a powered care bed.

That is the structural fact to understand before quoting. In Australia the bed is fundable, but the money has to be unlocked twice — once at the aged care assessment, and again at prescription. A supplier who reads the funding programme as a general market will spend a year waiting for orders that never clear.

The regulatory side has its own shape. A bed supplied as a medical device needs an entry on the Australian Register of Therapeutic Goods (ARTG), and only an Australian sponsor can hold that entry. A CE certificate helps, because the TGA accepts evidence from comparable overseas regulators, but it does not replace the entry.

This guide covers what an imported bed needs to be lawfully supplied, how funding reaches a household, and what the numbers say about the market underneath.

What changed on 1 November 2025

Support at Home commenced on 1 November 2025 under the Aged Care Act 2024, replacing Home Care Packages and the short-term restorative care programme. Providers set their own prices from the start, with government price caps scheduled to begin on 1 July 2026.

For equipment, the part that matters is the Assistive Technology and Home Modifications (AT-HM) scheme. It sits outside the participant's quarterly budget and is allocated in tiers set at the aged care assessment.

The high tier is the one a powered bed lives in. A simple height-adjustable bed can fit inside the medium tier. A rotating bed with powered positioning generally needs the high tier, and an item priced above A$15,390 needs a prescription as supporting evidence.

Two further rules shape the sale. A prescription has to come from a qualified clinician — an occupational therapist, physiotherapist or registered nurse — and must carry an item description, quotes and clinical justification. Funding is available for twelve months once approved, so a stalled quote does not sit indefinitely.

The list is also closed. An item that is not on the AT-HM list is not funded through this route, whatever its merits.

Who can supply: the sponsor holds the entry

Here the Australian system diverges from the British one. In the UK, a foreign manufacturer appoints a UK Responsible Person and registers the device itself. In Australia the manufacturer cannot hold the registration. An Australian legal entity, the sponsor, applies to include the device on the ARTG and becomes the party the TGA deals with for the life of the entry.

The sponsor's duties run well past paperwork: holding the entry and keeping it current, paying the annual charge, reporting adverse events, managing recalls and variations, and producing regulatory, technical and clinical information on request. A written agreement sets out the relationship, and the sponsor's name appears on the label.

A distributor who agrees to act as sponsor has taken on a regulatory role, with the duties that come with it. Expect them to ask harder questions than a buyer would, and have the technical file ready before the conversation starts.

The fees are modest next to the EU. For FY2026–27 an ARTG application for a Class IIa device is A$1,244, with an annual charge of A$1,305; an application audit, if one is selected, adds A$4,926 at level 1. The fee is the smallest part of a launch. What decides it is the technical file behind the application.

Classification: device or furniture, and which class

Australia classifies devices under Schedule 2 of the Therapeutic Goods (Medical Devices) Regulations 2002, and the rules do not map cleanly onto the EU classes. An electrically adjustable bed intended for a therapeutic purpose is an active device, and the common landing point is Class IIa. Beds configured for intensive care or respiratory support sit higher.

The class sets the conformity assessment route, and the sponsor's application has to carry the evidence for it.

There is a second fork, familiar from other markets. A bed sold purely as domestic furniture, with no therapeutic claim, may fall outside the device framework altogether. That is a legitimate category for a product designed and sold that way, and it carries a consequence in Australia that is easy to miss: AT-HM funding is assessed against a care need, and equipment sold without any care claim is difficult to place in that pathway. The regulatory route, the label and the marketing have to say the same thing.

The overseas certificate shortcut

The TGA maintains a list of comparable overseas regulators, and a notified-body certificate issued under the EU MDR is on it. For Class IIa, a notified-body quality management system certificate can support an ARTG application. Since a 2023 amendment, the TGA no longer requires the separate EU technical documentation certificate that the EU does not issue for that class.

What that buys is time and a narrower audit. Acceptance is still a separate decision, and four conditions decide whether the evidence holds:

• The evidence must cover the same device, with the same design, intended purpose and indications.
• The TGA remains the decision-maker, and can decline evidence it considers insufficient.
• Classification has to align. A device that lands in a different class in Australia needs the Australian route.
• The certificate must be current, and the body still designated.

MDSAP audit reports are also accepted, which shortens the path for a manufacturer already carrying one for other markets.

Three routes to a household

Not every bed reaches a home through the funding scheme. In practice there are three doors, and only one of them leads to a family paying in full.

The AT-HM route is the one that generates the most enquiry and the least certainty, because it depends on an assessment the buyer may not have had. The private route moves faster and is where most first sales in a new market actually happen.

What the money reaches

At 30 June 2025, 292,911 people were receiving home care, 6.3% more than a year earlier. More people were in home care than in permanent residential care, where 196,313 people lived. A further 96,709 people were waiting for a Home Care Package at their approved level, up 41% in twelve months.

The waiting list is the figure to read twice. Demand is queuing. For a large share of the market, the assessment is the bottleneck.

The tiers change how a sale works. A participant assessed at medium cannot buy a high-tier bed without a reassessment or a prescription that supports additional funding. A provider who builds a rotating bed into a care plan without checking the tier ends up carrying the cost.

Self-funding sits alongside the scheme, and it is larger than the tier values imply. A family that does not qualify, or does not want to wait, buys privately, and the comparison they make is with residential care. StewartBrown's December 2025 survey put the average full refundable accommodation deposit received at A$563,199 — the upfront amount a new resident pays for a room, before daily care fees. Against that, a care bed is a one-off purchase, and the question a family asks is how long it postpones the deposit and the weekly fees behind it.

The market behind it

The Australian Bureau of Statistics puts the population at about 27.5 million, of whom 4.7 million are aged 65 or over — 17% — and roughly 581,000 are 85 or over, about 2.1%. The 85-plus group is the one most likely to need help with transfers, and it is growing faster than the rest.

Occupancy in residential care is running near 95%, which leaves little slack when a hospital discharge needs a bed the same week. That pressure is what makes the home setting worth the paperwork: a bed that completes a transfer at home keeps a person out of a queue with no spare capacity.

How Australia compares

Suppliers already selling into Europe or Britain tend to arrive with a mental model, and it is usually the wrong one. The four markets differ in who holds the registration and who signs the cheque.

The Australian column is the outlier. Everywhere else, a foreign maker can hold its own authorisation and appoint a representative. Here the authorisation belongs to someone else, and that someone carries legal duties for as long as the device is supplied.

If you're importing or specifying

As a rotating home care bed manufacturer, we get asked for the same short document list by Australian dealers.

• The ARTG inclusion number, and the sponsor's name and address.
• The classification, and the conformity assessment route behind it.
• The notified-body certificate, with its expiry date and confirmation that the body is still designated.
• The test evidence: IEC 60601-1 and IEC 60601-2-52 reports, with the certificate of conformity as a summary of them.
• Whether the model appears on the AT-HM list, and at which tier.
• Spare parts and service arrangements in Australia, including who attends a fault and how quickly.
• The label, showing the sponsor's name.

A supplier who cannot say which of those is in place has not finished the Australian file, and the gap tends to surface at the first tender.

A short checklist before you ship to Australia

• Device included on the ARTG, entry current
• Australian sponsor appointed, named on labelling
• Classification confirmed under Schedule 2, with evidence to match
• Conformity assessment in place; EU certificate valid and body still designated
• IEC 60601-1 and IEC 60601-2-52 reports on file
• AT-HM listing checked, tier confirmed, prescription pathway understood
• Adverse event reporting and recall process agreed with the sponsor
• Spare parts and service capability confirmed in Australia
• Instructions and marketing claims consistent with the regulatory route

Part of our market guide series on care equipment compliance. We build rotating beds and nursing beds at AIDASTRA; if you are comparing suppliers for Australia, the questions above work on any of them.

Related Reading

→ Rotating Nursing Beds in the UK — MHRA, CE and NHS Continuing Healthcare
→ Rotating Nursing Beds in Europe — CE Marking and the Pflegeversicherung
→ Rotating Nursing Beds in the USA — FDA, Medicare and Medicaid
→ FAQ: Global Certifications for Nursing Beds
→ FAQ: Nursing Bed Total Cost of Ownership
→ B2B Partnership Guide — Download Edition

Sources

• Australian Government Department of Health, Disability and Ageing — Support at Home, including programme commencement on 1 November 2025 and the Assistive Technology and Home Modifications (AT-HM) scheme. Support at Home programme page · AT-HM scheme
• Aged Care Act 2024 — commencement and the legislative basis for Support at Home. Federal Register of Legislation
• Australian Government Department of Health — Support at Home service list and AT-HM list, including provider-priced items and the requirement to publish prices on My Aged Care. My Aged Care — Support at Home
• Therapeutic Goods Administration — Regulation of medical devices, ARTG inclusion, and the role and obligations of the Australian sponsor. TGA — medical devices
• Therapeutic Goods (Medical Devices) Regulations 2002 — Schedule 2 classification rules and conformity assessment procedures. Federal Register of Legislation
• TGA — Use of market authorisation evidence from comparable overseas regulators and assessment bodies for medical devices (including IVDs), including acceptance of EU notified-body certificates. TGA guidance
• TGA — fees and charges for medical devices, FY2026–27: ARTG application A$1,244 (Class IIa), annual charge A$1,305, application audit level 1 A$4,926. TGA — fees and charges
• Australian Institute of Health and Welfare / GEN Aged Care Data — Aged care data snapshot 2025 and Report on the Operation of the Aged Care Act 2024–25: 292,911 home care recipients, 196,313 permanent residential residents, 96,709 people waiting for a Home Care Package. GEN — aged care data
• Australian Bureau of Statistics — National, state and territory population, and population by age and sex: population about 27.5 million, 4.7 million aged 65+ (17%), 581,000 aged 85+ (2.1%). ABS — population
• StewartBrown — Aged Care Financial Performance Survey, December 2025: average full refundable accommodation deposit received A$563,199; residential occupancy near 95%. StewartBrown